埃克替尼治疗表皮生长因子受体敏感突变的晚期非小细胞肺癌获益患者的临床分析

Clinical analysis of Icotinib in treatment of epidermal growth factor receptor sensitive mutations in advanced non small cell lung cancer benefit

目的探讨埃克替尼治疗表皮生长因子受体（EGFR）敏感突变的晚期非小细胞肺癌获益患者的临床效果。方法选取2013年1月-2014年12月来我院治疗的68例EGFR敏感突变的晚期非小细胞肺癌获益患者，采用单双号随机分为甲乙两组，每组34例。给予甲组患者埃克替尼治疗，给予乙组患者吉非替尼治疗，对比观察两组患者总有效率、获益率、体力状况评分及不良反应发生情况。结果甲组患者总有效率为82．4％，乙组为76．5％，差异有统计学意义（P〈0．05）；甲组1年获益率及体力状况评分略优于乙组，2年获益率两组相当，差异无统计学意义（P〉0．05）；甲组患者不良反应发生率低于乙组（P〈0．05）。结论埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌患者效果显著，且不良反应小，值得临床推广。

Objective To explore clinical effect of Icotinib in treatment of epidermal growth factor receptor （EGFR） sensitive mutations in patients with advanced non-small cell lung cancer benefit.Methods 68 patients of EGFR sensi- tive mutations with advanced non-small cell lung cancer benefit in our hospital from January 2013 to December 2014 were selected and randomly divided into two groups by using single and double number,34 cases in each group.Group A were given Icotinib treatment,patients in group B were were given Gefitinib treatment,overall effective rate,benefit rate,physical status score and incidence of adverse reactions in two groups were compared and observed.Results Overall effective rate was 82.4% in group A,with 76.5% in group B,and the difference was statistically significant （P〈0.05）; 1 year benefit rate and physical status score in group A were slightly better than those in group B,and the difference was not statistically significant （P〉0.05）,2 years benefit rate was similar between two groups and had no statistical dif- ference （P〉0.05）;incidence of adverse reactions in group A were lower than those in group B（P〈0.05）.Conclusion Ico- tinib in treatment of EGFR sensitive mutation in patients with advanced non-small cell lung cancer has significant ef- fect,and less adverse reactions,it is worthy of clinical promotion.